Medscape

Development and Implementation of a Program to Assess Medical Patients' Need for Venous Thromboembolism Prophylaxis

Before the development of a formal VTE prophylaxis program, we needed to assess our current compliance with VTE prophylaxis, as the data from 2003 were not recent enough to accurately reflect current ...
Medscape

Pharmacologic Prophylaxis Against Venous Thromboembolism in Hospitalized Patients With Cirrhosis and Associated Coagulopathies

The earliest published study on this topic was a retrospective case–control study by Northup and associates [8] focusing on 113 inpatients with cirrhosis who had newly diagnosed VTE during hospital ...
The New England Journal of Medicine

Apixaban for Extended Treatment of Provoked Venous Thromboembolism

The appropriate duration of anticoagulation for venous thromboembolism (VTE) in patients who have a transient provoking factor (e.g., surgery, trauma, or immobility) and concomitant enduring risk ...
Healio

Patient factors impact risk of venous thromboembolism after THA, TKA

Please provide your email address to receive an email when new articles are posted on . Patient factors may have a greater impact on venous thromboembolism risk in those having total joint ...
ascopubs.org

Real world analysis of VTE incidence in lung cancer: A comprehensive assessment of the Khorana score and other clinical factors in predicting VTE incidence.

Safety of DOACs in Budd-Chiari syndrome: A real-world comparison from the TriNetX Global Collaborative Network. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does ...
News Medical

Reduced-dose apixaban proves effective in preventing blood clot recurrence in cancer patients

Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning medication for at least six months, followed by an additional 12 months of ...